03/10/2023
đđđĢđđđĢđĸđ§
āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻāĻāĻāĻŋ āĻāώā§āϧ āϝāĻž āϏāĻžāϧāĻžāϰāĻŖāϤ āĻ
ā§āϝāĻžāύā§āĻāĻŋāĻā§āϝāĻŧāĻžāĻā§āϞā§āϝāĻžāύā§āĻ āĻšāĻŋāϏāĻžāĻŦā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϝāĻŧ, āϝāĻžāϰ āĻ
āϰā§āĻĨ āĻāĻāĻŋ āĻļāϰā§āϰ⧠āϰāĻā§āϤ ââââāĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāϤ⧠āĻŦāĻžāϧāĻž āĻĻā§āϝāĻŧāĨ¤ āĻāĻāĻŋ Coumadin āĻāĻŦāĻ Jantoven āϏāĻš āĻāϰ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽā§āĻ āĻĒāϰāĻŋāĻāĻŋāϤāĨ¤ āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻāĻāĻāĻŋ āĻŽā§āĻāĻŋāĻ āĻāώā§āϧ, āϏāĻžāϧāĻžāϰāĻŖāϤ āĻā§āϝāĻžāĻŦāϞā§āĻ āĻāĻāĻžāϰ⧠āύā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāĨ¤
āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āϏāĻŽā§āĻĒāϰā§āĻā§ āĻŽā§āϞ āĻŦāĻŋāώāϝāĻŧāĻā§āϞāĻŋāϰ āĻŽāϧā§āϝ⧠āϰāϝāĻŧā§āĻā§:
āĻ
ā§āϝāĻžāύā§āĻāĻŋāĻā§āϝāĻŧāĻžāĻā§āϞā§āϝāĻžāύā§āĻ āĻ
ā§āϝāĻžāĻāĻļāύ: āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āϰāĻā§āϤ⧠āĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻžāϰ āĻĒā§āϰāĻā§āϰāĻŋāϝāĻŧāĻžāϰ āϏāĻžāĻĨā§ āĻāĻĄāĻŧāĻŋāϤ āĻāĻŋāĻā§ āĻĒā§āϰā§āĻāĻŋāύā§āϰ āϏāĻāĻļā§āϞā§āώāĻŖāĻā§ āĻŦāĻžāϧāĻž āĻĻāĻŋāϝāĻŧā§ āĻāĻžāĻ āĻāϰā§āĨ¤ āĻŦāĻŋāĻļā§āώāϤ, āĻāĻāĻŋ āĻā§āϞāĻāĻŋāĻ āĻĢā§āϝāĻžāĻā§āĻāϰ II, VII, IX, āĻāĻŦāĻ X, āϏā§āĻāϏāĻžāĻĨā§ āĻĒā§āϰā§āĻāĻŋāύ āϏāĻŋ āĻāĻŦāĻ āĻĒā§āϰā§āĻāĻŋāύ āĻāϏ, āϝāĻž āĻĒā§āϰāĻžāĻā§āϤāĻŋāĻ āĻ
ā§āϝāĻžāύā§āĻāĻŋāĻā§āϝāĻŧāĻžāĻā§āϞā§āύā§āĻāϏ āĻā§āĻĒāĻžāĻĻāύ⧠āĻšāϏā§āϤāĻā§āώā§āĻĒ āĻāϰā§āĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ:
āϰāĻā§āϤ āĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻž āĻĒā§āϰāϤāĻŋāϰā§āϧ: āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āϏāĻžāϧāĻžāϰāĻŖāϤ āϏā§āĻ āĻŦā§āϝāĻā§āϤāĻŋāĻĻā§āϰ āĻāύā§āϝ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻšāϝāĻŧ āϝāĻžāϰāĻž āĻ
āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āϰāĻā§āϤ ââāĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻžāϰ āĻā§āĻāĻāĻŋāϤ⧠āĻĨāĻžāĻā§āĨ¤ āĻāϰ āĻŽāϧā§āϝ⧠āϰāϝāĻŧā§āĻā§ āĻ
ā§āϝāĻžāĻā§āϰāĻŋāϝāĻŧāĻžāϞ āĻĢāĻžāĻāĻŦā§āϰāĻŋāϞā§āĻļāύ (āĻāĻāĻāĻŋ āĻ
āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻšāĻžāϰā§āĻā§āϰ āĻāύā§āĻĻ), āĻĄāĻŋāĻĒ āĻā§āĻāύ āĻĨā§āϰāĻŽā§āĻŦā§āϏāĻŋāϏ (āĻĄāĻŋāĻāĻŋāĻāĻŋ), āĻĒāĻžāϞāĻŽā§āύāĻžāϰāĻŋ āĻāĻŽāĻŦā§āϞāĻŋāĻāĻŽ (āĻĒāĻŋāĻ), āĻā§āϤā§āϰāĻŋāĻŽ āĻšāĻžāϰā§āĻ āĻāĻžāϞāĻ āĻāĻŦāĻ āĻāĻŋāĻā§ āĻšāĻžāϰā§āĻā§āϰ āĻ
āĻŦāϏā§āĻĨāĻžāĨ¤
āϏā§āĻā§āϰā§āĻ āĻĒā§āϰāϤāĻŋāϰā§āϧ: āĻ
ā§āϝāĻžāĻā§āϰāĻŋāϝāĻŧāĻžāϞ āĻĢāĻžāĻāĻŦā§āϰāĻŋāϞā§āĻļāύ āϰā§āĻā§āĻĻā§āϰ āĻā§āώā§āϤā§āϰā§, āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻĒā§āϰāĻžāϝāĻŧāĻ āϏā§āĻā§āϰā§āĻā§āϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāϤ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻšāϝāĻŧ, āϝāĻž āĻŽāϏā§āϤāĻŋāώā§āĻā§ āϰāĻā§āϤ ââââāĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻžāϰ āϏāĻŽāϝāĻŧ āĻāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻŽāύāĻŋāĻāϰāĻŋāĻ: āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύā§āϰ āϏā§āĻŦāϤāύā§āϤā§āϰ āĻŦā§āĻļāĻŋāώā§āĻā§āϝāĻā§āϞāĻŋāϰ āĻŽāϧā§āϝ⧠āĻāĻāĻāĻŋ āĻšāϞ āĻāϰ āĻĒā§āϰāĻāĻžāĻŦāĻā§āϞāĻŋ āϝāϤā§āύ āϏāĻšāĻāĻžāϰ⧠āύāĻŋāϰā§āĻā§āώāĻŖ āĻāĻŦāĻ āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖ āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻā§āϰāĻšāĻŖāĻāĻžāϰ⧠āϰā§āĻā§āĻĻā§āϰ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āϰāĻā§āϤ ââââāĻĒāϰā§āĻā§āώāĻž āĻāϰāĻžāϤ⧠āĻšāĻŦā§, āϏāĻžāϧāĻžāϰāĻŖāϤ INR (āĻāύā§āĻāĻžāϰāύā§āϝāĻžāĻļāύāĻžāϞ āύāϰāĻŽāĻžāϞāĻžāĻāĻāĻĄ āϰā§āĻļāĻŋāĻ) āĻĒāϰā§āĻā§āώāĻž āĻŦāϞāĻž āĻšāϝāĻŧ, āϝāĻžāϤ⧠āϤāĻžāĻĻā§āϰ āϰāĻā§āϤ ââāĻāĻāĻāĻŋ āϞāĻā§āώā§āϝ āϏā§āĻŽāĻžāϰ āĻŽāϧā§āϝ⧠āĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻā§āĨ¤ āĻāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞā§āϰ āĻāĻĒāϰ āĻāĻŋāϤā§āϤāĻŋ āĻāϰ⧠āĻĄā§āĻ āϏāĻŽāύā§āĻŦāϝāĻŧ āĻāϰāĻž āĻšāϝāĻŧāĨ¤
āĻĄāĻžāϝāĻŧā§āĻ āĻāĻŦāĻ āĻāώā§āϧā§āϰ āϏāĻžāĻĨā§ āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋāϝāĻŧāĻž: āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻŦāĻŋāĻāĻŋāύā§āύ āĻāĻžāĻŦāĻžāϰā§āϰ āϏāĻžāĻĨā§ āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋāϝāĻŧāĻž āĻāϰā§, āĻŦāĻŋāĻļā§āώ āĻāϰ⧠āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻā§ āϏāĻŽā§āĻĻā§āϧ (āϝā§āĻŽāύ āĻļāĻžāĻ-āϏāĻŦā§āĻ) āĻāĻŦāĻ āĻāĻŋāĻā§ āĻ
ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžāϝāĻŧā§āĻāĻŋāĻ āĻāĻŦāĻ āĻāĻāĻžāϰ-āĻĻā§āϝ-āĻāĻžāĻāύā§āĻāĻžāϰ āĻāώā§āϧ āϏāĻš āĻ
āϏāĻāĻā§āϝ āĻāώā§āϧā§āϰ āϏāĻžāĻĨā§āĨ¤ āĻāĻ āĻŽāĻŋāĻĨāϏā§āĻā§āϰāĻŋāϝāĻŧāĻžāĻā§āϞāĻŋ āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύā§āϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āĻāĻŦāĻ āϏā§āϰāĻā§āώāĻžāĻā§ āĻĒā§āϰāĻāĻžāĻŦāĻŋāϤ āĻāϰāϤ⧠āĻĒāĻžāϰā§, āϤāĻžāĻ āĻāύāĻŋāώā§āĻ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻ
āĻĒāϰāĻŋāĻšāĻžāϰā§āϝāĨ¤
āĻĒāĻžāϰā§āĻļā§āĻŦ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻž: āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύā§āϰ āϏāĻžāϧāĻžāϰāĻŖ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻžāĻā§āϞāĻŋāϰ āĻŽāϧā§āϝ⧠āϰāϝāĻŧā§āĻā§ āϰāĻā§āϤāĻĒāĻžāϤ (āϝāĻž āϏāĻžāĻŽāĻžāύā§āϝ āĻŦāĻž āĻā§āϰā§āϤāϰ āĻšāϤ⧠āĻĒāĻžāϰā§), āĻā§āώāϤ āĻāĻŦāĻ āϤā§āĻŦāĻā§āϰ āύā§āĻā§āϰā§āϏāĻŋāϏ (āϤā§āĻŦāĻā§āϰ āĻāĻŋāϏā§āϝā§āϰ āĻŽā§āϤā§āϝā§)āĨ¤ āϰā§āĻā§āĻĻā§āϰ āϰāĻā§āϤāĻĒāĻžāϤā§āϰ āϞāĻā§āώāĻŖ āϏāĻŽā§āĻĒāϰā§āĻā§ āϏāĻā§āϤāύ āĻšāĻāϝāĻŧāĻž āĻāĻŦāĻ āϤāĻžāĻĻā§āϰ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏā§āĻŦāĻž āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āĻā§ āϰāĻŋāĻĒā§āϰā§āĻ āĻāϰāĻž āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
āϰāĻŋāĻāĻžāϰā§āϏāĻžāϞ: āϰāĻā§āϤāĻĒāĻžāϤā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻŦāĻž āĻāϰā§āϰ⧠āĻ
āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϞā§, āϰāĻŋāĻāĻžāϰā§āϏāĻžāϞ āĻāĻā§āύā§āĻ āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧ (āϝā§āĻŽāύ, āĻāĻŋāĻāĻžāĻŽāĻŋāύ āĻā§ āĻŦāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒā§āϰāϤāĻŋāώā§āϧāĻ āϝā§āĻŽāύ āĻĻāĻžāĻŦāĻŋāĻāĻžāϤā§āϰāĻžāύā§āϰ āĻāύā§āϝ āĻāĻĻāĻžāϰā§āϏāĻŋāĻā§āĻŽāĻžāĻŦ)āĨ¤ āĻāĻā§āϞāĻŋ āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύā§āϰ āĻ
ā§āϝāĻžāύā§āĻāĻŋāĻā§āϝāĻŧāĻžāĻā§āϞā§āϝāĻžāύā§āĻ āĻĒā§āϰāĻāĻžāĻŦāĻā§āϞāĻŋāĻā§ āĻĻā§āϰā§āϤ āĻŦāĻŋāĻĒāϰā§āϤ āĻāϰāϤ⧠āϏāĻšāĻžāϝāĻŧāϤāĻž āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏāĻŽāϝāĻŧāĻāĻžāϞ: āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻĨā§āϰāĻžāĻĒāĻŋāϰ āϏāĻŽāϝāĻŧāĻāĻžāϞ āĻāĻŋāĻāĻŋāϤā§āϏāĻžāϰ āĻāύā§āϝ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāĻŋāĻāĻŋāϤā§āϏāĻžāϰ āĻ
āĻŦāϏā§āĻĨāĻžāϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰ āĻāϰ⧠āĻĒāϰāĻŋāĻŦāϰā§āϤāĻŋāϤ āĻšāϝāĻŧāĨ¤ āĻāĻŋāĻā§ āϰā§āĻā§ āĻ
āϏā§āĻĨāĻžāϝāĻŧā§āĻāĻžāĻŦā§ āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻā§āϰāĻšāĻŖ āĻāϰāϤ⧠āĻĒāĻžāϰ⧠(āϝā§āĻŽāύ, āĻ
āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻĒāϰ⧠āĻŦāĻž āϤā§āĻŦā§āϰ āĻāĻŽāĻžāĻ āĻŦāĻžāĻāϧāĻž), āĻ
āύā§āϝāĻĻā§āϰ āĻāĻāĻŋ āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻā§ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻā§āϰāĻšāĻŖāĻāĻžāϰ⧠āĻŦā§āϝāĻā§āϤāĻŋāĻĻā§āϰ āĻāύā§āϝ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āϰāĻā§āϤ ââāĻĒāϰā§āĻā§āώāĻž āĻāĻŦāĻ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖ āĻāĻžāĻĻā§āϝāĻžāĻā§āϝāĻžāϏ āĻŦāĻāĻžāϝāĻŧ āϰāĻžāĻāĻž āϏāĻš āϤāĻžāĻĻā§āϰ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏā§āĻŦāĻž āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāĻžāĻŦāϞ⧠āϏāĻžāĻŦāϧāĻžāύ⧠āĻ
āύā§āϏāϰāĻŖ āĻāϰāĻž āĻ
āϤā§āϝāύā§āϤ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ āĻāĻĒāϰāύā§āϤā§, āϤāĻžāĻĻā§āϰ āĻāĻāĻŋāϤ āϤāĻžāĻĻā§āϰ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāϏā§āĻŦāĻž āĻĒā§āϰāĻĻāĻžāύāĻāĻžāϰā§āĻā§ āϤāĻžāĻĻā§āϰ āĻāώā§āϧ āĻŦāĻž āĻāĻžāĻĻā§āϝāĻžāĻā§āϝāĻžāϏā§āϰ āĻā§āύ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āϏāĻŽā§āĻĒāϰā§āĻā§ āĻ
āĻŦāĻšāĻŋāϤ āĻāϰāĻž āĻāĻŦāĻ āϰāĻā§āϤāĻĒāĻžāϤ āĻŦāĻž āĻ
āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻĒāϏāϰā§āĻā§āϰ āĻāύā§āϝ āϏāϤāϰā§āĻ āĻĨāĻžāĻāĻžāĨ¤ āĻāϝāĻŧāĻžāϰāĻĢāĻžāϰāĻŋāύ āĻāĻāĻāĻŋ āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠āĻāώā§āϧ āϝāĻžāϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻāĻŦāĻ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āϏāϤāϰā§āĻ āĻŦā§āϝāĻŦāϏā§āĻĨāĻžāĻĒāύāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
đđđĢđđđĢđĸđ§ is a medication commonly used as an đđđđđđđđđđđđđ, which means it helps prevent the formation of blood clots in the body. It is also known by its brand names, including Coumadin and Jantoven. Warfarin is an oral medication, typically taken in the form of a tablet.
đ˛đđ đđđđđđ đđđđđ đđđđđđđđ đđđđđđ
đ:
đ¨đđđđđđđđđđđđ đ¨đđđđđ: Warfarin works by inhibiting the synthesis of certain proteins in the blood that are involved in the clotting process. Specifically, it interferes with the production of clotting factors II, VII, IX, and X, as well as protein C and protein S, which are natural anticoagulants.
đ´đđ
đđđđ đŧđđđ:
đŠđđđđ
đĒđđđ đˇđđđđđđđđđ: Warfarin is commonly prescribed to individuals who are at risk of forming abnormal blood clots. This includes people with atrial fibrillation (an irregular heart rhythm), deep vein thrombosis (DVT), pulmonary embolism (PE), artificial heart valves, and certain heart conditions.
đēđđđđđ đˇđđđđđđđđđ: In patients with atrial fibrillation, warfarin is often prescribed to reduce the risk of stroke, which can occur when blood clots travel to the brain.
đ´đđđđđđđđđ: One of the distinctive features of warfarin is that its effects need to be carefully monitored and controlled. Patients taking warfarin must undergo regular blood tests, usually called INR (International Normalized Ratio) tests, to ensure that their blood is clotting within a target range. Dosing adjustments are made based on these test results.
đ°đđđđđđđđđđ đđđđ đĢđđđ đđđ
đ´đđ
đđđđđđđđ: Warfarin interacts with various foods, particularly those rich in vitamin K (such as leafy greens), and with numerous medications, including some antibiotics and over-the-counter drugs. These interactions can affect the effectiveness and safety of warfarin, so close monitoring is essential.
đēđđ
đ đŦđđđđđđ: Common side effects of warfarin include bleeding (which can be minor or serious), bruising, and skin necrosis (death of skin tissue). It's important for patients to be aware of signs of bleeding and report them to their healthcare provider.
đšđđđđđđđ: In case of bleeding or the need for emergency surgery, there are reversal agents available (e.g., vitamin K or specific antidotes like idarucizumab for dabigatran). These can help rapidly reverse the anticoagulant effects of warfarin.
đĢđđđđđđđ đđ đŧđđ: The duration of warfarin therapy varies depending on the medical condition it is being used to treat. Some patients may take warfarin temporarily (e.g., after surgery or an acute clot), while others may need it long-term.
đ°đ'đ đđđđđđđ đđđ đđđ
đđđđ
đđđđ đđđđđđ đđđđđđđđ đđ đđđđđđ đđđđđ đđđđđđđđđđ đđđđđđ
đđ'đ đđđđđđđđđđđđ đđđđđđđđđ, đđđđđđ
đđđ đđđđđđđ đđđđđ
đđđđđđđ đđđ
đđđđđđđđđđđ đđđđđđđđđđ đ
đđđđđđ đđđđđđ. đ¨đ
đ
đđđđđđđđđ, đđđđ đđđđđđ
đđđđđđ đđđđđ đđđđđđđđđđ đđđđđđ
đđ đđ đđđ đđđđđđđ đđ đđđđđ đđđ
đđđđđđđ đđ đ
đđđ đđđ
đđ đđđđđđđđ đđđ đđđđđ đđ đđđđđ
đđđ đđ đđđđđđđ đđđđđđđđ. đžđđđđđđđ đđ đ đđđđđđđđ đđđ
đđđđđđđ đđđđ đđđđđđđđ đđđđđđđ đđđđđđđđđđ đđ đđđđđđ đđđ đđđđđđ đđđ
đđđđđđđđđđđđđ.